Xeris Biopharma Holdings Inc (NASDAQ: XERS) open the trading on Wednesday, with great promise as it jumped 4.76% to $2.20, before settling in for the price of $2.10 at the close. Taking a more long-term approach, XERS posted a 52-week range of $1.46-$3.26.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 195.35%. Meanwhile, its Annual Earning per share during the time was 38.13%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 16.41%. This publicly-traded company’s shares outstanding now amounts to $138.13 million, simultaneously with a float of $137.79 million. The organization now has a market capitalization sitting at $326.17 million. At the time of writing, stock’s 50-day Moving Average stood at $2.00, while the 200-day Moving Average is $2.13.
Xeris Biopharma Holdings Inc (XERS) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Xeris Biopharma Holdings Inc’s current insider ownership accounts for 7.06%, in contrast to 38.76% institutional ownership. According to the most recent insider trade that took place on May 10 ’24, this organization’s Director bought 5,400 shares at the rate of 1.91, making the entire transaction reach 10,314 in total value, affecting insider ownership by 16,400. Preceding that transaction, on Mar 14 ’24, Company’s Director bought 4,500 for 2.16, making the whole transaction’s value amount to 9,720. This particular insider is now the holder of 11,000 in total.
Xeris Biopharma Holdings Inc (XERS) Earnings and Revenue Records
So, what does the last quarter earnings report of the company that was made public on 3/31/2024 suggests? It has posted -0.14 earnings per share (EPS) beating the forecaster’s viewpoint (set at -0.13) by -0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.09 per share during the current fiscal year.
Xeris Biopharma Holdings Inc’s EPS increase for this current 12-month fiscal period is 16.41% and is forecasted to reach -0.17 in the upcoming year.
Xeris Biopharma Holdings Inc (NASDAQ: XERS) Trading Performance Indicators
Let’s observe the current performance indicators for Xeris Biopharma Holdings Inc (XERS). It’s Quick Ratio in the last reported quarter now stands at 1.81. The Stock has managed to achieve an average true range (ATR) of 0.12. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 1.90.
In the same vein, XERS’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.46, a figure that is expected to reach -0.10 in the next quarter, and analysts are predicting that it will be -0.17 at the market close of one year from today.
Technical Analysis of Xeris Biopharma Holdings Inc (XERS)
[Xeris Biopharma Holdings Inc, XERS] recent stats showed that its last 5-days Average volume was poorer than the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 26.40% While, its Average True Range was 0.11.
Raw Stochastic average of Xeris Biopharma Holdings Inc (XERS) in the period of the previous 100 days is set at 32.48%, which indicates a major rise in contrast to 30.23% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 28.18% that was lower than 64.43% volatility it exhibited in the past 100-days period.
